The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

ANAB

AnaptysBio, Inc.

Healthcare · Biotechnology

Overall research band Mixed
Quality Mixed
Valuation Very weak
Balance sheet Exceptional
Market confirmation Not available

One-minute company read

What this report can tell you now

What the company does

AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing immunology therapeutics for autoimmune and inflammatory diseases in the United States. Its main products include Rosnilimab, which completed a Phase 2b trial for moderate-to-severe rheumatoid arthritis; ANB033, in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody in Phase 1a trial; dostarlimab, a PD-1 antagonist for solid tumors; and Imsidolimab, an antibody in Phase 3 development for generalized pustular psoriasis. The company advances antibody programs through preclinical and clinical milestones and generates revenue through collaborations, including agreements with GSK and Vanda.

The current research profile is Industrial Company. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC58.0%Model input; read with the evidence status and period context.
Operating margin20.4%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years38.8%Model input; read with the evidence status and period context.
FCF margin8.4%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.